• Policy
• Authorization rate for No.16 is still 0%
• by Lee, Hye-Kyung Sep 18, 2023 05:26am

• Policy
• Celltrion receives approval for Nesina Met SR
• by Lee, Hye-Kyung Sep 15, 2023 05:33am

• Policy
• Which P-CAB generic will come first, K-CAB or Vocinti?
• by Lee, Tak-Sun Sep 15, 2023 05:33am

• Company
• nAMD tx Vabysmo can be prescribed at general hospitals
• by Eo, Yun-Ho Sep 15, 2023 05:33am

• Company
• Gilead Sciences Korea appoints Jae-Yeon Choi as new head
• by Eo, Yun-Ho Sep 15, 2023 05:33am

• Policy
• Imfinzi recieves RSA reevals and seeks to extend reimb
• by Lee, Tak-Sun Sep 15, 2023 05:32am

• Policy
• Reevaluation difficult for Ildong and Abbott’s Lypsta
• by Lee, Tak-Sun Sep 14, 2023 06:40am

• Company
• Wellysis receives FDA approval for electrocardiograph
• by Nho, Byung Chul Sep 14, 2023 06:40am

• Policy
• [Reporter's view] Focus on non-face-to-face contraceptives
• by Lee, Jeong-Hwan Sep 14, 2023 06:37am

• Company
• Hanmi will focus on anti-obesity drugs... from GLP-1 to DTx
• by Kim, Jin-Gu Sep 14, 2023 06:37am